Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.

ABSTRACT:

Background

The prognosis for patients with disseminated lung cancer is poor and current treatments have limited survival benefit as resistance often occurs, and is often associated with significant toxicity. A possible strategy to improve treatment and evade chemoresistance may be to find new combinations of drugs. The aim of this study was to analyze the potential of combining proteasome inhibitors (PIs) with chemotherapeutic drugs used in the routine treatment for lung cancer patients.

Results

The median-effect method was applied to the Fluorometric Microculture Cytotoxicity Assay (FMCA) to evaluate effects of combining two different PIs (bortezomib and b-AP15) with clinically used chemotherapeutic drugs representing different mechanisms of action (cisplatin, gefitinib, ge

SUBMITTER: Sooman L 

PROVIDER: S-EPMC5667477 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature